JP2024516291A5 - - Google Patents
Info
- Publication number
- JP2024516291A5 JP2024516291A5 JP2023567973A JP2023567973A JP2024516291A5 JP 2024516291 A5 JP2024516291 A5 JP 2024516291A5 JP 2023567973 A JP2023567973 A JP 2023567973A JP 2023567973 A JP2023567973 A JP 2023567973A JP 2024516291 A5 JP2024516291 A5 JP 2024516291A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- compound according
- alkyl
- unsubstituted
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163183612P | 2021-05-03 | 2021-05-03 | |
| US63/183,612 | 2021-05-03 | ||
| US202163282686P | 2021-11-24 | 2021-11-24 | |
| US63/282,686 | 2021-11-24 | ||
| PCT/US2022/027535 WO2022235717A1 (en) | 2021-05-03 | 2022-05-03 | Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516291A JP2024516291A (ja) | 2024-04-12 |
| JP2024516291A5 true JP2024516291A5 (https=) | 2025-05-13 |
Family
ID=81750835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023567973A Pending JP2024516291A (ja) | 2021-05-03 | 2022-05-03 | ベンゾイミダゾイルｇｌｐ－１受容体アゴニスト、それを含む医薬組成物、及びそれらの使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20220396569A1 (https=) |
| EP (2) | EP4334304A1 (https=) |
| JP (1) | JP2024516291A (https=) |
| AU (1) | AU2022271223A1 (https=) |
| BR (1) | BR112023022836A2 (https=) |
| CA (1) | CA3217720A1 (https=) |
| MX (1) | MX2023012918A (https=) |
| WO (1) | WO2022235717A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3192601A1 (en) * | 2020-08-21 | 2022-02-24 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| WO2023029380A1 (zh) | 2021-08-30 | 2023-03-09 | 杭州德睿智药科技有限公司 | 作为glp1r激动剂的新型芳醚取代杂环类化合物 |
| PT4408840T (pt) | 2021-09-27 | 2025-10-07 | Terns Pharmaceuticals Inc | Ácidos benzimidazolocarboxílicos como agonistas de glp-1r |
| CN118401519A (zh) | 2021-10-25 | 2024-07-26 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| US20250042882A1 (en) | 2021-12-16 | 2025-02-06 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| WO2023111144A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| CN119095843A (zh) | 2022-02-23 | 2024-12-06 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| CN117362282B (zh) * | 2022-07-07 | 2026-04-21 | 杭州德睿智药科技有限公司 | Glp-1r激动剂的盐及其制备方法和应用 |
| EP4562006A1 (en) * | 2022-07-27 | 2025-06-04 | Carmot Therapeutics, Inc. | N-heterocylic gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| WO2024051700A1 (zh) * | 2022-09-05 | 2024-03-14 | 德睿智药(苏州)新药研发有限公司 | 作为glp1r激动剂的新型芳基氘代苄醚取代杂环类化合物 |
| EP4592285A1 (en) | 2022-09-22 | 2025-07-30 | Shionogi & Co., Ltd. | Fused ring compound having glp-1 receptor agonist effect |
| KR20250085816A (ko) | 2022-11-16 | 2025-06-12 | 일라이 릴리 앤드 캄파니 | 글루카곤-유사 펩티드 1 수용체 효능제 |
| CN116217522B (zh) * | 2023-02-22 | 2025-06-24 | 广东莱佛士制药技术有限公司 | Glp-1受体激动剂关键中间体的手性纯化方法 |
| EP4568664B1 (en) | 2023-04-07 | 2026-04-01 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity |
| CN120981457A (zh) | 2023-09-14 | 2025-11-18 | 歌礼制药(中国)有限公司 | Glp-1r激动剂及其治疗方法 |
| TW202521534A (zh) | 2023-11-24 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
| WO2026073030A1 (en) | 2024-09-27 | 2026-04-02 | Carmot Therapeutics Inc. | Combination therapy of peptide tyrosine-tyrosine (pyy) analogues and glp-1r agonists |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060275288A1 (en) | 2005-01-20 | 2006-12-07 | Grihalde Nelson D | GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof |
| US20120148586A1 (en) | 2009-08-27 | 2012-06-14 | Joyce Ching Tsu Chou | Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders |
| US20120021979A1 (en) | 2010-06-24 | 2012-01-26 | Vanderbilt University | GLP-1 receptor modulation of addiction, neuropsychiatric disorders and erectile dysfunction |
| KR102314286B1 (ko) * | 2016-12-16 | 2021-10-21 | 화이자 인코포레이티드 | Glp-1 수용체 작용제 및 이의 용도 |
| US10934279B2 (en) * | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| MA54555A (fr) * | 2018-11-22 | 2021-09-29 | Qilu Regor Therapeutics Inc | Agonistes de glp-1r et leurs utilisations |
| EP3953344A4 (en) * | 2019-04-12 | 2023-08-09 | Qilu Regor Therapeutics Inc. | GLP-IR AGONISTS AND THEIR USES |
| WO2020234726A1 (en) * | 2019-05-20 | 2020-11-26 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
| TWI751585B (zh) * | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| WO2021096284A1 (ko) * | 2019-11-15 | 2021-05-20 | 일동제약(주) | Glp-1 수용체 작용제 및 이의 용도 |
| CN114761395B (zh) * | 2019-12-02 | 2024-11-15 | 现代药品株式会社 | Glp-1受体激动剂 |
-
2022
- 2022-05-03 EP EP22725069.3A patent/EP4334304A1/en active Pending
- 2022-05-03 AU AU2022271223A patent/AU2022271223A1/en not_active Abandoned
- 2022-05-03 MX MX2023012918A patent/MX2023012918A/es unknown
- 2022-05-03 BR BR112023022836A patent/BR112023022836A2/pt unknown
- 2022-05-03 JP JP2023567973A patent/JP2024516291A/ja active Pending
- 2022-05-03 US US17/736,070 patent/US20220396569A1/en not_active Abandoned
- 2022-05-03 WO PCT/US2022/027535 patent/WO2022235717A1/en not_active Ceased
- 2022-05-03 EP EP24203388.4A patent/EP4461355A3/en not_active Withdrawn
- 2022-05-03 US US18/558,647 patent/US20240262811A1/en active Pending
- 2022-05-03 CA CA3217720A patent/CA3217720A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024516291A5 (https=) | ||
| FI78697B (fi) | Foerfarande foer framstaellning av terapeutiskt aktiva benzisotiazol- och benzisoxazolpiperazinderivat. | |
| JPH04506522A (ja) | 置換イミダゾール | |
| JP2006503888A5 (https=) | ||
| JP2009537524A5 (https=) | ||
| JP2013511511A5 (https=) | ||
| RU2583430C2 (ru) | Пиразольные соединения, обладающие терапевтическим эффектом на множественную миелому | |
| JP2009525340A5 (https=) | ||
| JP2002526442A (ja) | プロスタグランジンｅ２アンタゴニストの新規用途 | |
| JP2006511587A5 (https=) | ||
| WO2003097637A1 (en) | (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker | |
| DK158351B (da) | Analogifremgangsmaade til fremstilling af substituerede 4-fenylalkylimidazolderivater eller farmaceutisk acceptable syreadditionssalte deraf | |
| JP2011145659A5 (https=) | ||
| CA2018700A1 (en) | Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals | |
| JP2025502943A5 (https=) | ||
| JP2008517020A5 (https=) | ||
| JP2024546678A5 (https=) | ||
| WO2007069712A1 (ja) | アミン化合物及びその医薬用途 | |
| JP2005517008A5 (https=) | ||
| JP2005513004A5 (https=) | ||
| JP2015504917A5 (https=) | ||
| CN102131803A (zh) | (1r，2s，3r)-1-(2-(异噁唑-3-基)-1h-咪唑-4-基)丁烷-1，2，3，4-四醇的固体形式及其使用方法 | |
| JP2023531411A5 (https=) | ||
| JP6194306B2 (ja) | アミン化合物及びその医薬用途 | |
| JP2013544794A5 (https=) |